HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Application of Neurokinin-1 Receptor in Targeted Strategies for Glioma Treatment. Part I: Synthesis and Evaluation of Substance P Fragments Labeled with 99mTc and 177Lu as Potential Receptor Radiopharmaceuticals.

Abstract
Gliomas, particularly WHO grade IV glioblastoma multiforme, are one of the most common and aggressive primary tumors of the central nervous system. The neuropeptide, substance P (SP), is the physiological ligand of the neurokinin-1 (NK-1) receptor that is consistently overexpressed in glioblastoma cells. The aim of this work was to study physico-chemical and biological properties of different SP analogues labeled with technetium-99m and lutetium-177 radionuclides. The synthesized compounds were characterized in vitro by partition coefficients (logP) and their stability was investigated in various physiological solutions. Biological properties (Kd, Bmax) were characterized using the U373 MG cell line. The obtained lipophilicity values of the [99mTc]NS₃/CN-SP and [177Lu]DOTA-SP radiobioconjugates were in the range of -0.3 to +0.6 and -2.5 to -5.0, respectively. The studied radiobioconjugates were stable in PBS buffer and CSF, as well as in 10 mM histidine and/or cysteine solutions whereas in human serum showed enzymatic biodegradation. [177Lu]DOTA-[Thi⁸,Met(O₂)11]SP(1⁻11), [177Lu]DOTA-SP(4⁻11) and [177Lu]DOTA-[Thi⁸,Met(O₂)11]SP(5⁻11) radiobioconjugates bound specifically to NK-1 receptors expressed on glioblastoma cells with affinity in the nanomolar range. To conclude, the shorter analogues of SP can be used as vectors, nevertheless they still do not fulfil all requirements for preparations in nuclear medicine.
AuthorsAgnieszka Majkowska-Pilip, Przemysław Koźmiński, Anna Wawrzynowska, Tadeusz Budlewski, Bogusław Kostkiewicz, Ewa Gniazdowska
JournalMolecules (Basel, Switzerland) (Molecules) Vol. 23 Issue 10 (Oct 05 2018) ISSN: 1420-3049 [Electronic] Switzerland
PMID30301182 (Publication Type: Journal Article)
Chemical References
  • Ligands
  • Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Neurokinin-1
  • Substance P
  • Lutetium
  • Technetium
  • Lutetium-177
Topics
  • Cell Line, Tumor
  • Gene Expression Regulation, Neoplastic (genetics)
  • Glioma (drug therapy, genetics, pathology)
  • Humans
  • Isotope Labeling (methods)
  • Ligands
  • Lutetium (chemistry)
  • Molecular Targeted Therapy
  • Radioisotopes (chemistry)
  • Radionuclide Imaging
  • Radiopharmaceuticals (chemistry, pharmacology)
  • Receptors, Neurokinin-1 (genetics)
  • Substance P (analogs & derivatives, genetics, pharmacology)
  • Technetium (chemistry)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: